title: A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
abstract: Ibrutinib is a first-in-class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.
authors.affiliation: Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA.
authors.forename: Natalie
authors.initials: N
authors.lastname: Wallace
authors.affiliation: Yale Comprehensive Cancer Center and VA Connecticut Healthcare System West Haven Connecticut USA.
authors.forename: Ellice
authors.initials: E
authors.lastname: Wong
authors.affiliation: Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA.
authors.forename: Dennis
authors.initials: D
authors.lastname: Cooper
authors.affiliation: Yale Comprehensive Cancer Center and VA Connecticut Healthcare System West Haven Connecticut USA.
authors.forename: Herta
authors.initials: H
authors.lastname: Chao
keywords: Arrhythmia; cardiomyopathy; ibrutinib; mantle cell lymphoma; tyrosine kinase inhibitor